Literature DB >> 33130972

Identification of key genes and biological pathways in lung adenocarcinoma via bioinformatics analysis.

Yuanyuan Wang1, Zihao Zhou1, Liang Chen1, Yuzheng Li1, Zengyuan Zhou1, Xia Chu2.   

Abstract

Lung adenocarcinoma (LUAD) accounts for the majority of cancer-related deaths worldwide. Our study identified key LUAD genes and their potential mechanism via bioinformatics analysis of public datasets. GSE10799, GSE40791, and GSE27262 microarray datasets were retrieved from the Gene Expression Omnibus (GEO) database. The RobustRankAggreg package was used to perform a meta-analysis, and 50 upregulated genes and 87 downregulated genes overlapped in three datasets. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID). Furthermore, protein-protein interaction (PPI) networks of the differentially expressed genes (DEGs) were built by the Search Tool for the Retrieval of Interacting Genes (STRING) and 22 core genes were identified by Molecular Complex Detection (MCODE) and visualized with Cytoscape. Subsequently, these core genes were analyzed by the Kaplan-Meier Plotter and Gene Expression Profiling Interactive Analysis (GEPIA). The results showed that all 22 genes were significantly associated with reduced survival rates. For GEPIA, the expression of only one gene was not significantly different between LUAD tissues and normal tissues. A KEGG pathway enrichment reanalysis of the 21 genes identified five key genes (CCNB1, BUB1B, CDC20, TTK, and MAD2L1) in the cell cycle pathway. Finally, the Comparative Toxicogenomics Database (CTD) website was used to explore the relationship between these key genes and certain drugs. Based on the bioinformatics analysis, five key genes were identified in LUAD, and drugs closely associated these genes can provide clues for the treatment and prognosis of LUAD.

Entities:  

Keywords:  Bioinformatics analysis; Differentially expressed genes; Lung adenocarcinoma; Therapeutic targets

Mesh:

Substances:

Year:  2020        PMID: 33130972     DOI: 10.1007/s11010-020-03959-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  48 in total

Review 1.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Authors:  Christos Sotiriou; Martine J Piccart
Journal:  Nat Rev Cancer       Date:  2007-07       Impact factor: 60.716

2.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 3.  Gene-expression profiling in vaccine therapy and immunotherapy for cancer.

Authors:  Davide Bedognetti; Ena Wang; Mario Roberto Sertoli; Francesco M Marincola
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

Review 4.  Clinical impact of high-throughput gene expression studies in lung cancer.

Authors:  Jennifer Beane; Avrum Spira; Marc E Lenburg
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

Review 5.  Evolving strategies for global gene expression analysis of cancer.

Authors:  Bradley P Coe; Raj Chari; William W Lockwood; Wan L Lam
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

Review 6.  Gene expression profiling of non-small cell lung cancer.

Authors:  Sunil Singhal; Daniel Miller; Suresh Ramalingam; Shi-Yong Sun
Journal:  Lung Cancer       Date:  2008-04-25       Impact factor: 5.705

7.  Clinical relevance of mutant-allele tumor heterogeneity and lung adenocarcinoma.

Authors:  Hengyu Mao
Journal:  Ann Transl Med       Date:  2019-09

8.  NCBI GEO: archive for functional genomics data sets--10 years on.

Authors:  Tanya Barrett; Dennis B Troup; Stephen E Wilhite; Pierre Ledoux; Carlos Evangelista; Irene F Kim; Maxim Tomashevsky; Kimberly A Marshall; Katherine H Phillippy; Patti M Sherman; Rolf N Muertter; Michelle Holko; Oluwabukunmi Ayanbule; Andrey Yefanov; Alexandra Soboleva
Journal:  Nucleic Acids Res       Date:  2010-11-21       Impact factor: 16.971

9.  Clinical Value and Prospective Pathway Signaling of MicroRNA-375 in Lung Adenocarcinoma: A Study Based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Bioinformatics Analysis.

Authors:  Ting-Qing Gan; Wen-Jie Chen; Hui Qin; Su-Ning Huang; Li-Hua Yang; Ye-Ying Fang; Lin-Jiang Pan; Zu-Yun Li; Gang Chen
Journal:  Med Sci Monit       Date:  2017-05-23

10.  Long Non-coding RNA JHDM1D-AS1 Interacts with DHX15 Protein to Enhance Non-Small-Cell Lung Cancer Growth and Metastasis.

Authors:  Guodong Yao; Kexin Chen; Yu Qin; Yangyang Niu; Xuefang Zhang; Shidong Xu; Chi Zhang; Meiyan Feng; Kuan Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-10       Impact factor: 8.886

View more
  8 in total

1.  Let-7c-5p Restrains Cell Growth and Induces Apoptosis of Lung Adenocarcinoma Cells via Targeting ESPL1.

Authors:  Xiang Liu; Wei Zeng; Dayang Zheng; Min Tang; Wangyan Zhou
Journal:  Mol Biotechnol       Date:  2022-05-31       Impact factor: 2.860

2.  Comprehensive Bioinformatics Analysis to Identify the Gene HMMR Associated With Lung Adenocarcinoma Prognosis and Its Mechanism of Action in Multiple Cancers.

Authors:  Jianguang Shi; Yingqi Chen; Zishan Wang; Jin Guo; Changyong Tong; Jingjie Tong; Wentao Hu; Chenwei Li; Xinjian Li
Journal:  Front Oncol       Date:  2021-10-06       Impact factor: 6.244

Review 3.  Multimerin-1 and cancer: a review.

Authors:  Mareike G Posner
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

4.  Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis.

Authors:  Qian Chen; Sibo Yang; Yewei Zhang; Bo Li; Huanming Xu; Shi Zuo
Journal:  Biomed Res Int       Date:  2022-01-28       Impact factor: 3.411

5.  Enhancer-associated regulatory network and gene signature based on transcriptome and methylation data to predict the survival of patients with lung adenocarcinoma.

Authors:  Shihao Huang; Shiyu Chen; Di Zhang; Jiamei Gao; Linhua Liu
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

6.  ASPM, CDC20, DLGAP5, BUB1B, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma.

Authors:  Qiaoling Zhang; Yingmei Wang; Fengxia Xue
Journal:  Genet Res (Camb)       Date:  2022-09-17       Impact factor: 1.375

7.  Integrated analysis of the molecular mechanisms in idiopathic pulmonary fibrosis.

Authors:  Ke Zhu; Aiqun Xu; Wanli Xia; Pulin Li; Rui Han; Enze Wang; Sijing Zhou; Ran Wang
Journal:  Int J Med Sci       Date:  2021-08-02       Impact factor: 3.738

8.  NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma.

Authors:  Yan Tang; Chunsheng Hu
Journal:  Dis Markers       Date:  2021-07-12       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.